Abstract This article describes in a sequential fashion how ab initio quantum mechanical methods can be applied to study the pharmacophoric features of drugs. It also describes how accurate drugâ€“receptor interaction calculations can guide the careful design of balanced dual inhibitors, which form an important class of second generation drugs. As an example, the authors have chosen balanced inhibitors of angiotensin converting enzyme/neutral endopeptidase (ACE/NEP) as modern antihypertensive drugs. A unified, accurate, in silico design approach is presented, encompassing all steps from pharmacophore derivation to complete understanding of mechanistic aspects leading to drug design. FigureLisinopril docked in angiotensin converting enzyme (ACE) model
pharmacophoric      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Pharmacophore         

drugs                         0.9999963346526882^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Drug                  

pharmacophore                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Pharmacophore         

angiotensin converting enzyme 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Angiotensin-converting_enzyme

fashion                       0.9989866497252239^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Fashion               

ab initio                     0.9936766228772421^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Ab_initio_quantum_chemistry_methods

drug design                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Drug_design           

ACE                           0.9999999619591343^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Angiotensin-converting_enzyme

angiotensin converting enzyme 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Angiotensin-converting_enzyme

inhibitors                    0.999999999971692^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Enzyme_inhibitor      

antihypertensive drugs        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Antihypertensive_drug 

inhibitors                    0.999999999971692^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Enzyme_inhibitor      

mechanistic                   0.9999307543779894^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Reaction_mechanism    

quantum mechanical            0.9872890427305762^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Quantum_mechanics     

NEP                           0.9499242702536006^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/New_Economic_Policy   

ACE                           0.9999999619591343^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Angiotensin-converting_enzyme

dual                          0.9401052007839813^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Dual_space            

drugs                         0.9999963346526882^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Drug                  

neutral endopeptidase         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Neprilysin            

